ABSTRACT: More than 360 million humans are affected with some degree of hearing loss, either early or later in life. A genetic cause for the disorder is present in a majority of the cases. We mapped a locus (DFNB101) for hearing loss in humans to chromosome 5q in a consanguineous Pakistani family. Exome sequencing revealed an insertion mutation in GRXCR2 as the cause of moderateto-severe and likely progressive hearing loss in the affected individuals of the family. The frameshift mutation is predicted to affect a conserved, cysteine-rich region of GRXCR2, and to result in an abnormal extension of the C-terminus. Functional studies by cell transfections demonstrated that the mutant protein is unstable and mislocalized relative to wild-type GRXCR2, consistent with a loss-of-function mutation. Targeted disruption of Grxcr2 is concurrently reported to cause hearing loss in mice. The structural abnormalities in this animal model suggest a role for GRXCR2 in the development of stereocilia bundles, specialized structures on the apical surface of sensory cells in the cochlea that are critical for sound detection.
Introduction
Auditory thresholds in affected individuals with recessively inherited deafness can range from mild to profound hearing loss, which can be stable or progressive in nature. Among the nonsyndromic forms, up to 85% of inherited deafness is autosomal recessive and exhibits high genetic heterogeneity, with more than 75 associ- in a small subset of the identified genes result in less severe and/or progressive hearing loss [Naz 2012; Schraders et al., 2012; Schrauwen et al., 2012; Yariz et al., 2012; Girotto et al., 2013; Horn et al., 2013] , a majority of the known recessive mutations are associated with profound, congenital deafness. Conversely, a high proportion of humans suffer from a progressive or early onset, less severe hearing loss, which suggests that alternative mutations in known or novel genes contributing to this phenotype remain unidentified. Globally, mutations in TECTA (MIM #602574), STRC (MIM #606440), CABP2 (MIM #607314), OTOGL (MIM #614925), and BDP1 (MIM #607012) have been reported to cause moderate-tosevere hearing loss, whereas mutations in OTOG (MIM #604887) result in moderate hearing loss. Consanguineous families from Pakistan have played a significant role in mapping and identification of genes required for audition, especially those that on disruption cause recessively inherited profound deafness. Similar progress has not been made in identification of genes involved in moderate-tosevere hearing loss. We sought to study this phenotype in Pakistani families and here report a mutant allele of GRXCR2 associated with recessively inherited, moderate-to-severe hearing loss in humans.
Materials and Methods

Ethics Statement
Institutional review board at the School of Biological Sciences, University of the Punjab, Lahore, Pakistan approved the study prior to the commencement of research, and sampling was conducted with written informed consent of all participants.
Subjects
We investigated individuals affected with moderate-to-severe hearing loss in a cohort that included 80 consanguineous families with three or more affected individuals (Naz S, unpublished data) . We also included samples from 55 sporadic individuals born in consanguineous marriages with no known environmental causes for their hearing loss and who were negative for mutations in GJB2 and other common genes involved in hearing loss. The ears of the participants were clinically examined by an ENT (ear, nose, and throat) doctor. Hearing was evaluated by pure-tone audiometry at frequencies of 250, 500, 2,000, 4,000, and 8,000 Hz in ambient noise conditions. Clinically, hearing loss was defined as moderate (41-55 dB), moderate-to-severe (56-70 dB) or severe hearing loss (71-90 dB), respectively. Vestibular dysfunction or balance issues were evaluated by Romberg and Tandem gait tests. Funduscopy and electroretinography were conducted to detect onset of retinitis pigmentosa.
Homozygosity Mapping
Known genes for hearing loss including those for Usher syndromes were excluded by linkage analyses with polymorphic markers [Imtiaz and Naz, 2012] . Genome-wide homozygosity mapping was performed for three individuals in family HLAI-05 (one unaffected mother and her two affected offspring) on SNP data obtained from Affymetrix Genome-wide Human SNP array 6.0 (Atlas Biolabs, Berlin, Germany). Regions of shared homozygosity between the two affected were searched with KinSNP [Amir el et al., 2010] . For these analyses, a minimum block threshold was set at 0.5 cm and the confidence cutoff values for SNPs were set at 0.1. A heterozygous SNP in any stretch of 10 homozygous SNPs was ignored in order not to miss regions of homozygosity due to erroneous allele calls.
Whole-Exome Sequencing
Whole-exome sequencing was performed for individual V:3 using Agilent V4 enrichment kit (Agilent Technologies, Santa Clara, CA) and paired-end reads were obtained at 50× coverage on an Illumina Hi-Seq 2000 sequencer (Otogenetics, Norcross, GA). The reads were mapped to UCSC hg19 reference human genome (http://genome.ucsc.edu/). The data were analyzed and variants were filtered using the DNAnexus software (DNAnexus, Mountain View, CA). Known SNPs in dbSNP132 were filtered out. Data from known deafness genes were examined for mutations. Subsequent analysis was confined to the mapped DFNB101 linkage interval.
Primers were designed (Supp . Table S1 ) using the online program primer 3 (http://bioinfo.ut.ee/primer3-0.4.0/). All primer pairs except PCDHGA12 were used to PCR amplify the respective exons with surrounding intronic regions in 25 μl reactions at 2 mM final MgCl 2 concentration using a touchdown protocol from 65°C to 55°C. PCDHGA12 exon was GC-rich and was amplified by a different protocol (Supp. Table S1 ). All PCR products were purified and sequenced using Big Dye Terminators v3.1 (Applied Biosystems, Foster City, CA). Frequency of mutations in SPOCK1, PCDHGA12, and GRXCR2 was checked by allele-specific PCR in normal control samples (Supp. Table S2 ). We submitted the novel variants that we identified to dbSNP (http://www.ncbi. nlm.nih.gov/SNP/).
Protein Alignment and Prediction
GRXCR2 orthologous protein sequences were obtained from Ensembl Genome Server (www.ensembl.org). Multiple sequence alignments of the protein sequences were carried out using CLUSTALO (http://www.ebi.ac.uk/Tools/msa/clustalo/). Protein structural predictions and homology searches were performed by Predict Protein (https://www.predictprotein.org/) and NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Transfection Constructs and Assays
Human inner ear tissue was obtained with appropriate informed consent and under the approval of the University of Michigan Institutional Review Board (IRB HUM00051822). Total RNA was prepared from human inner ear tissue using Trizol (Life Technologies, Grand Island, NY); reverse transcribed using oligo dT primers, amplified with primers designed from wild-type human GRXCR2 cDNA sequence (NM 001080516.1; forward primer: gtga attcgccaccatggagcagaagctgatctcagaggaggacctgGAGGACCCTGAGA AAAAGCTGAA; reverse primer: gtggatccGGAAGGATAATTTTA-GAACCAGTTTCAA), and cloned into the EcoRI-BamHI sites of the expression vector pIRES-eGFP (Clontech, Mountain View, CA). The forward primer included an in-frame myc epitope coding region (underlined) to permit translation of an N-terminally tagged GRXCR2 protein. The reverse primer is complementary to 3 UTR sequences that extended 248 nucleotides 3 of the wild-type translation stop codon and 60 nucleotides 3 of the new stop codon predicted from the frameshift in the c.714dupT transcript. The pIRES vector is designed to coexpress eGFP from a downstream internal ribosome entry site. The c.714dupT variant was introduced into the wild-type cDNA using the QuikChange II XL Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Agilent Technologies). Clones were confirmed by Sanger sequencing.
Immunocytochemistry
LLC-PK1-CL4 (CL4) epithelial cells on glass coverslips were transfected with GRXCR2 expression constructs (2 μg per coverslip) using Lipofectamine LTX (Life Technologies). Cells were fixed 24 hr after transfection in 2% paraformaldehyde, permeabilized with 0.1% Triton X-100, and washed in PBS. Cells were then treated with 5% goat serum in PBS for 1 hr and incubated with a mouse anti-myc monoclonal antibody (catalogue number 05-419 [9E10]; Millipore, Billerica, MA). After washing in PBS, cells were incubated with antimouse IgG-Alexa 594 secondary antibodies (Life Technologies). Native fluorescence from the GFP reporter protein was augmented by coincubation with anti-GFP antibodies (Cell Signaling Technology, Boston, MA) and antirabbit IgG-Alexa 488 secondary antibodies. Nuclei and actin filaments were stained using Hoechst reagent and phalloidin-Alexa 647 (Life Technologies). Following additional PBS washes and mounting with Prolong Gold (Life Technologies), cells were imaged using a Nikon A1 confocal microscope with an oil-immersion objective (60×, 1.4 numerical aperture). Orthogonal sections (x, z) were generated using Imaris 7.6 software (Bitplane, Zurich, Germany). Colocalization of myc-GRXCR2 and actin filament immunoreactivity was quantitatively evaluated by the Imaris software, using its automatic thresholding function [Costes et al., 2004] .
Western Blot Analysis
Human embryonic kidney 293T cells in 6-well plates were transfected with GRXCR2 expression constructs (2 μg per well) using Lipofectamine LTX (Life Technologies). Transfected cells were treated with the reversible proteasome inhibitor MG132 (Cayman Chemical, Ann Arbor, MI) at a final concentration of 20 μM or with ethanol vehicle. Whole-cell protein lysates were prepared approximately 24 hr after transfection (6 hr after treatment with MG132 or ethanol) in RIPA buffer (150 mM NaCl; 1.0% NP-40; 0.5% sodium deoxycholate; 0.1% SDS, 50 mM Tris, pH 8.0) supplemented with a protease inhibitor cocktail (Roche, Indianapolis, IN) and 0.3 mM phenylmethylsulfonyl fluoride. Protein concentrations of each lysate were measured using the DC assay system (Biorad, Hercules, CA). Equivalent amounts of total protein were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose filters. Filters were blocked with 5% dry milk in PBS/0.05% Tween 20 and sequentially incubated with a mouse monoclonal antibody specific for myc (catalog number R950-25; Life Technologies) and C5SCAB1 is a custom-generated marker to genotype repeats present at chr5:126250460-126250504 according to hg19 assembly. The GRXCR2 mutation is shown ("+", wild-type allele; "−", dupT allele). Samples from IV:2, V:1, and V:3 were used for the SNP homozygosity screen, whereas that of V:3 was used for exome sequencing. B: Audiograms from selected individuals in family HLAI-05. Thresholds reveal the presence of moderate-to-severe, sensorineural hearing loss, which was reported to be early in onset in the three affected individuals. For clarity, thresholds are shown for one ear from each individual. There was no difference in hearing between the two ears of an affected person. Note that the younger individuals have a less severe hearing loss as compared with the older affected individual, which suggests that the loss in hearing is progressive in nature. C: Partial chromatograms from GRXCR2 exon 3 from an affected and a control individual, respectively. The duplicated "T" residue is underlined.
antimouse IgG conjugated to horseradish peroxidase (ThermoScientific, Waltham, MA). Immune complexes were detected with SuperSignal West Femto Chemiluminescent Substrate (ThermoScientific) and imaged with a CCD camera. Following detection of myc hybrid proteins, the immune complexes were removed from the filters with Restore Western Blot Stripping Buffer (Thermoscientific) and GFP was detected using a rabbit anti-GFP antibody (Cell Signaling) and antirabbit IgG conjugated to horseradish peroxidase.
Results
Family HLAI-05 (Fig. 1A) was ascertained from Punjab. Examinations of the ears of the affected individuals showed intact tympanic membranes and excluded inner ear infections as a cause of hearing loss. Audiometry was first performed when the affected individuals V:1 and V:3 were 12 and 9 years old, respectively, and 2 years later. The affected child V:5 was 8 years old when the family was reexamined, and his audiometry was also performed at that time. All three affected individuals segregate a bilateral, symmetric, moderate-to-severe sensorineural hearing loss (Fig. 1B) .
Reports by the parents suggested that the affected individuals had normal hearing until approximately 2 years of age and responded to commands comparable to their unaffected children at the same age. Subsequently, three children were affected by mild hearing loss that rapidly worsened by the time they were 4 years old. A recent study has demonstrated that parental concerns are reliable and one of the major factors in diagnosing hearing defects after children pass newborn hearing screens [Dedhia et al., 2013] . A comparison of the audiometric profile of the three affected individuals (Fig. 1B) also confirms the parents' observation. The youngest individual had better hearing and oral speech as compared with the two older individuals and the oldest affected individual had the highest hearing thresholds. No significant progression of hearing loss for the oldest affected individuals was recorded when audiometry was repeated after 2 years. The three affected individuals in family HLAI-05 do not use hearing aids but still have limited oral speech. The thresholds of hearing of the unaffected individuals varied between 20 and 40 dB (Fig. 1B) . These levels are comparable to thresholds recorded in the normal population in Pakistan when audiometry is conducted in the field [Riazuddin et al., 2000] (Naz S, unpublished data).
The three affected individuals had normal balance as assessed by history and vestibular testing. Independent ambulation was not delayed and was comparable to that of the unaffected siblings. Ophthalmological examinations demonstrated normal, peripheral, and central visual acuity in both daylight and in reduced light. Funduscopy did not detect the presence of retinal abnormalities and electroretinographs were also normal, which ruled out the onset of retinitis pigmentosa at the time of examination. Since detailed medical examination showed the absence of visual and obvious manifestations of any other disorder, we concluded that affected individuals in family HLAI-05 most likely have nonsyndromic hearing loss.
The hearing loss in HLAI-05 did not segregate with any of the reported recessively inherited deafness causing genes. Analyses of genome-wide SNP data identified eight regions in the genome at which marker alleles were homozygous in the two affected individuals and heterozygous in the unaffected mother (Supp . Tables S3  and S4 ). Genotyping was performed on samples from the whole family with microsatellite markers that spanned these intervals and only linkage to a 30-cM region on chromosome 5q was supported with a LOD score of 2.7 (Fig. 1A) . This locus has now been designated as DFNB101 by HUGO gene nomenclature committee. The mapped interval includes approximately 350 genes, many of which have been reported to exhibit high expression in the inner ear (Shared Harvard Inner Ear Laboratory Database, SHIELD https://shield.hms.harvard.edu/). The DFNB101 candidate region also includes two previously identified genes associated with nonsyndromic hearing loss, DIAPH1 and POU4F3, and two currently unknown dominant deafness gene loci (DFNA42 and DFNA54).
To identify DFNB101 gene, we analyzed the data after exome sequencing. No mutations were identified in any of the known deafness causing genes. About 97% of the coding exons (including exonintron boundaries) within the DFNB101 region were sequenced at coverage greater than 10×. We identified three novel variants located in the interval that were absent from dbSNP, exome variant server (http://evs.gs.washington.edu/EVS/), and 1000 genome project (http://www.1000genomes.org/) datasets: a frameshift variant in GRXCR2 (p.G239WfsX74) and nonsynonymous variants in SPOCK1 (p.R110S) and in PCDHGA12 (p.P220R) (Supp. Table S5 ). All three variants were confirmed by Sanger sequencing of respective PCR products (Supp . Table S1 ) and were heterozygous in obligate carriers and homozygous in the affected individuals. The frequency of the three variants was evaluated using DNA samples from ethnically matched controls. The two missense variants were found at frequencies ࣙ0.05 and are therefore likely neutral polymorphisms. The third variant, c.714dupT (Chr5:145239330) (Fig. 1C) in GRXCR2 (Glutaredoxin-like cysteine-rich 2), was absent from 150 normal controls (300 chromosomes). This variant was considered a likely pathogenic mutation primarily due to its severity. Exome variant server does list one among 6,259 individuals who is a carrier for a frameshift mutation in GRXCR2 (c.252delA, p.I85SfsX33). However, we still considered c.714dupT mutation to be the variant responsible for the phenotype in affected individuals in family HLAI-05 since we expected homozygous mutations to cause hearing loss. Additionally, targeted deletion of the murine ortholog Grxcr2 causes severe hearing loss in mice [Avenarius, 2012] , which supports the role of its ortholog GRXCR2 in human hearing.
GRXCR2 comprises three exons ( Fig. 2A) . The human mRNA and EST sequences of the gene available in the public databases are derived from a source of many pooled tissues. RNAseq data (IlluminaBodyMap) indicate that GRXCR2 has very low expression in the heart, testis, and adrenal gland. Protein expression data (Model Organism Protein Expression Database, moped.proteinspire.org/) indicates a low titer of GRXCR2 in blood plasma. This suggests that GRXCR2 expression is fairly limited in humans, comparable to mice in which all publicly available EST and MPSS signatures are derived from inner ear cDNA libraries.
GRXCR2 is predicted to encode a protein of 248 amino acids in humans (Fig. 2B) . The orthologous proteins exhibit high similarity at the N-and C-termini and are present only in vertebrate genomes (Fig. 2C) . Overall, GRXCR2 is 38% identical and 47% similar to its paralog, GRXCR1. Two groups of four cysteines at the C-terminus of GRXCR2 are predicted to fold into a zinc finger configuration and their arrangement (CX 2 CX 7 CX 2 CX 20 CX 2 CX 7 CX 2 C) is highly conserved in all orthologs (Fig. 2C) and between GRXCR2 and GRXCR1. The mutation c.714dupT is predicted to remove conserved residues, including the last two cysteines from the zinc finger motif, and to generate a protein with an abnormal C-terminal extension (Fig. 2D) .
Sanger sequencing of GRXCR2 did not identify any variants that segregate with hearing loss in the DFNA42-(Xua K, personal communication) or DFNA54-(Gürtler N, personal communication) linked families. The phenotype in these two families could be due to mutations elsewhere in GRXCR2 or in different genes. GRXCR2 mutations were not identified in the remainder of our cohort of moderate-to-severe recessive hearing loss (mostly congenital) or in another collaborative screen of over 600 congenital profound deafness cases (Avenarius et al., submitted) , suggesting that GRXCR2 may not be a frequent cause of this type of genetic deafness.
To evaluate potential effects of the c.714dupT variant, we prepared GRXCR2 expression constructs that encoded myc-tagged, wild-type GRXCR2 (myc-GRXCR2 wt ) or the C-terminal truncation/extension protein predicted from the c.714dupT variant, also tagged with a myc epitope (myc-GRXCR2 var ). We transfected the wild type and c.714dupT variant constructs into an epithelial cell line, LLC-PK1-CL4 (CL4) using previously described methods [Loomis et al., 2003] . CL4 cells are derived from porcine kidney and have been used as models of epithelial cells [Loomis et al., 2003 ]. In addition, CL4 microvilli have similarity to hair cell stereocilia and undergo dimensional changes upon expression of proteins such as the actin bundling protein espin, consistent with espin's role in stereocilia morphogenesis in vivo [Loomis et al., 2003] . Following transfection of an expression construct encoding wild-type, myc-tagged GRXCR2 (myc-GRXCR2 wt ), high levels of anti-myc immunoreactivity were observed near the apical surface of CL4 cells (Fig. 3A-C , A -C ). This signal was closely associated with actin filaments on the apical surface of the cells, consistent with selective localization of GRXCR2 wt to microvilli (Supp. Fig. S1 ). Similar localization has been demonstrated in CL4 cells transfected with mouse Grxcr1 [Odeh et al., 2010] and Grxcr2 (Kohrman DC, unpublished data) and suggests that human GRXCR2, like these related proteins, also resides in the stereocilia of sensory hair cells in the inner ear in vivo. In contrast, only a small fraction (less than 5%) of CL4 cells transfected with the myc-GRXCR2 var construct exhibited myc-immunoreactivity (Fig. 3D-F, D'-F') , which was present at lower levels in the cytoplasm rather than in microvilli. The majority of GRXCR2 var -transfected cells (greater than 95% of GFPpositive cells) exhibited little or no specific immunoreactivity (Supp. Fig. S2 ).
Western analysis of whole-cell protein lysates prepared from transfected human embryonic kidney 293T cells indicated much reduced steady-state levels of GRXCR2 var relative to GRXCR2 is also introduced. Evolutionary conserved cysteine residues are marked by asterisks, two of which are predicted to be affected by the frameshift mutation.
( Fig. 4) . Lower levels of GRXCR2 var may be due to an increase in its proteasomal degradation rate as a result of structural alterations induced by the C-terminal truncation/extension, similar to a recently described frameshift mutations in POU3F4 [Choi et al., 2013] . Consistent with this notion, increased levels of the variant protein were observed following treatment of the transfected cells with the proteasome inhibitor MG132 (Fig. 4) . The stability and localization defects of the GRXCR2 var protein are consistent with a loss of function of the c.714dupT mutant allele.
Discussion
We have identified a frameshift mutation in GRXCR2 that is implicated in early onset, progressive, moderate-to-severe hearing loss. The mutation c.714dupT affects the last two cysteines in the zinc finger motif of GRXCR2. Zinc finger motifs have been shown in different proteins to be important for protein-protein interactions including homo-or hetero-dimerization [Gamsjaeger et al., 2007] . The mutation is also predicted to generate an abnormal C-terminal or GRXCR2 var expression constructs, the vector control plasmid, or were mock transfected. Duplicate transfections were treated with 20 μM proteasome inhibitor MG132 (+) or with ethanol vehicle (−). Western analysis of whole-cell protein lysates from the transfected cells indicated GRXCR2 wt steady-state levels were significantly higher than GRXCR2 var levels, which were increased following proteasome inhibition. The positions of myc-GRXCR2 wt (expected molecular weight: 29.5 kDa) and myc-GRXCR2 var (expected molecular weight: 36.7 kDa) are indicated (top panel). The anti-myc antibody also recognizes the cellular c-myc protein, levels of which are stabilized by proteasome inhibitors. The levels of GFP indicate comparable transfection efficiencies of each construct (bottom panel).
extension of the protein. This 63 amino acid C-terminal extension does not contain sequence homology or domains similar to known proteins. However, the extension introduces an N-glycosylation motif (NISL) that can facilitate the degradation of proteins that fail to achieve their native conformation [Vembar and Brodsky, 2008] . Consistent with this notion, our cell transfection assays with variant GRXCR2 suggested that the mutant protein is unstable.
GRXCR2 is a paralog of GRXCR1. Mutations of GRXCR1 cause moderate-to-profound hearing loss in humans [Odeh et al., 2010; Schraders et al., 2010] . In addition, several independent, loss-offunction alleles of Grxcr1 result in deafness in pirouette mice [Odeh et al., 2010] . GRXCR1 orthologs are present in diverse metazoan species in contrast to GRXCR2 orthologs, which are limited to the vertebrate genomes. GRXCR2 orthologs have conserved N-and C-termini, whereas the central portion is the most diverse and has similarity to glutaredoxins. Glutaredoxins are enzymes that reduce oxidized cysteines of proteins, using glutathione as an electron donor [Holmgren, 2000] . However, the paired catalytic cysteine residues present in active glutaredoxins and the three amino acids that are predicted to be required for contact with glutathione [Holmgren, 1989] are absent from GRXCR2. This suggests that the central domain of GRXCR2 does not possess glutaredoxin activity.
The GRXCR1 and GRXCR2 homolog thrumin1 (A. thaliana) encodes a protein that also lacks the sites important for enzymatic activity and does not have a demonstrated catalytic function.
THRUMIN1 is required for light-induced chloroplast movement, during which its actin bundling activity appears to facilitate linkage between the plasma membrane of the chloroplast and the underlying actin cytoskeleton [Whippo et al., 2011] . PLP2, another oxidoreductase superfamily member, also lacks catalytic cysteine residues and, through interactions with chaperone TCP-1, facilitates the folding of cytosolic actins in yeast [McCormack et al., 2009] . Stereocilia of the mammalian inner ear also contain cytoplasmic β-and γ -actin. GRXCR2 is localized to the stereocilia in the mouse inner ear [Avenarius, 2012] . The actin bundling and folding functions of these homologs suggest a similar role of GRXCR2 in the development of stereocilia bundles in the mammalian inner ear.
The targeted Grxcr2 mouse mutant exhibits hearing loss that is early onset and progressive in nature [Avenarius, 2012] comparable to the loss that we have demonstrated in individuals with mutation in GRXCR2. Hearing loss in the mouse Grxcr2 mutant is associated with defects in the early development and later maintenance of stereocilia bundle organization. The similarity in the human phenotype with targeted mice mutant suggests a comparable requirement of the protein for the maintenance of cochlear function in both species.
